DPP-4 and GLP-1: Can They Be Used Together? (October 2026)

01 · The short answer

Can DPP-4 and GLP-1 medicines be used together?

Whether a DPP-4 inhibitor and a GLP-1 medicine can be used together depends on your prescriber's judgement. The honest position is that this is a prescribing decision made against the product information, your diabetes history and everything else you take.

If you take a gliptin today and are considering a GLP-1 medicine, the safest step is a conversation with the clinician who manages your diabetes. Our guide to whether they can be given together goes into the question from the prescribing side.

Do not stop a diabetes medicine because you have read something online. Stopping can affect blood sugar control, and the right order of changes is for your prescriber to set.

02 · At a glance

How the two classes compare

03 · What to do next

Is this relevant to you, and what should you do?

This question matters if you already take a gliptin and are being offered, or are considering, a GLP-1 treatment. It matters less if you are not on any diabetes medicine and are looking at weight management alone. In that case there is no DPP-4 inhibitor to combine with anything.

If you are weighing up a private GLP-1 treatment, the practical route is to complete a free consultation, where a GPhC-registered prescriber reviews your health history and current medicines. Declare every medicine, including any gliptin. Our weight loss clinic explains the options.

Related guides: Rowe glp1 and Pmos glp1.

04 · What DPP-4 inhibitors are

What DPP-4 inhibitors are

DPP-4 inhibitors, usually called gliptins, are a class of type 2 diabetes medicine. Sitagliptin is the name most people recognise. The class is built around the enzyme DPP-4, which is where the name comes from.

If you need specifics, the patient leaflet for your own gliptin and your prescriber are the right sources.

A DPP-4 inhibitor is not a weight-loss injection, and it is not a GLP-1 medicine. If a product name ends in "gliptin", it belongs to this class. If it is semaglutide, liraglutide or tirzepatide, it does not.

For a deeper look at the biology behind both classes, our page on the DPP-4 and GLP-1 mechanism of action covers the hormone side in more detail.

05 · What GLP-1 medicines do

What GLP-1 medicines do

GLP-1 medicines act on a natural gut-hormone receptor. Tirzepatide, the active ingredient in Mounjaro, is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1.¹ Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.

In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹ That dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic).

So when someone asks "is Ozempic a DPP-4 inhibitor?", the answer is no. Ozempic is semaglutide licensed for type 2 diabetes — it is not a UK weight-loss medicine. The two names sound alike because both classes are called incretin-based, but they are different drugs with different mechanisms.

06 · Why people ask about combining

Why people ask about combining them

The question usually arises because both classes are described as incretin-based, so it seems logical that using both might help more. Whether that logic holds in practice is a clinical question, and it is exactly the sort of thing a prescriber weighs against the product information.

It also arises from stepwise diabetes care. Someone may already be on a gliptin, then be offered a GLP-1 medicine because their blood sugar or weight needs more support. At that point the sensible question is not "can I just add it?" but "should the gliptin continue, change or stop?"

None of the related pages on the DPP-4 and GLP-1 combination replaces your own prescriber's advice.

07 · Telling your prescriber

What to tell your prescriber before starting Mounjaro

List every medicine you take, including diabetes tablets such as gliptins, insulin and anything bought over the counter. Because Mounjaro slows stomach emptying, it can affect how quickly some oral medicines are absorbed, particularly when you start treatment or increase the dose. Tell your prescriber about everything you take — especially warfarin or other narrow-margin medicines, insulin, or sulfonylureas (where doses may need reducing to avoid low blood sugar).¹

Two interactions are worth knowing by name. With insulin or sulfonylureas, doses may need adjusting because of the risk of low blood sugar; they are not simply barred from being used with Mounjaro.¹ And Mounjaro slows stomach emptying, which can reduce how well oral contraceptive pills are absorbed.⁷ The SmPC advises switching to a non-oral method, or adding a barrier method (such as condoms), for 4 weeks after starting Mounjaro and for 4 weeks after each dose increase.¹

Our own consultation is free and is reviewed by a GPhC-registered prescriber, who can see all of this before anything is approved.

08 · Mounjaro for diabetes and weight

Mounjaro for diabetes and for weight management

In the UK, Mounjaro is licensed for weight management in adults and for type 2 diabetes.¹ NICE has separate guidance for each use, with one appraisal for diabetes and another for overweight and obesity.⁸⁴ The diabetes pathway is where the gliptin question usually appears.

For weight management, the headline trial is SURMOUNT-1. In that trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages, individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.

A separate trial, SURPASS-2, compared tirzepatide with semaglutide in people with type 2 diabetes.³ It is a GLP-1-class comparison, not a DPP-4 one, so it should not be read as evidence about gliptins.

09 · NHS and private access

NHS and private access

Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

If you take diabetes medicines through your GP or diabetes team, raise any change with them first. They hold your full record and can coordinate the switch or the addition.

10 · Side effects and reporting

New symptoms and how to report them

If you start a new medicine, or change a combination, and notice a new symptom, tell your prescriber. Do not assume it is harmless or that it is expected. A symptom that is not on the UK patient leaflet list is not a listed side effect, so tell your prescriber about any new or lasting symptom.

You can also report a suspected side effect through the MHRA Yellow Card scheme.¹⁹ Reports help regulators spot patterns, including ones that only appear when medicines are used together.

Our aftercare includes ongoing monthly reviews and side-effect support from the prescribing team, so you are not left to work out an unexpected reaction alone.

11 · Stopping and clearance

If treatment changes: how long Mounjaro stays in the body

If your prescriber decides to change your regimen, it helps to know that tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system.¹ There is no way to speed this up, and nothing needs doing while it clears.

That matters when two medicines overlap. A prescriber planning a switch has to allow for the time a once-weekly injection stays active, which is a further reason not to improvise changes at home.

12 · Serious side effects

Serious side effects: when to get help straight away

Serious side effects are uncommon but need urgent attention. Seek immediate medical help for: severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin/eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you take insulin or a sulfonylurea alongside Mounjaro, watch for low blood sugar (shakiness, sweating, confusion) — your prescriber may need to adjust those medicines.¹